{
    "info": {
        "nct_id": "NCT04956692",
        "official_title": "A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab, Administered With Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants With Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer",
        "inclusion_criteria": "* Has pathologically (histologically or cytologically) confirmed diagnosis of squamous or nonsquamous non-small cell lung cancer (NSCLC)\n* Has Stage IV (T any, N any, M1a, M1b, or M1c - American Joint Committee on Cancer 8th Edition) squamous or nonsquamous NSCLC\n* Has confirmation that epidermal growth factor receptor (EGFR), Anaplastic lymphoma kinase (ALK), or ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS1)-directed therapy is not indicated in nonsquamous NSCLC as well as mixed nonsquamous/squamous NSCLC. Participants with purely squamous NSCLC do not require testing\n* Has not received prior systemic treatment for their metastatic NSCLC. Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease\n* Has an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0 or 1\n* Male participants are eligible to participate if they agree to use contraception as per protocol unless confirmed to be azoospermic\n* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of childbearing potential (WOCBP) or is a WOCBP who agrees of using a contraceptive method per protocol\n* Has measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by the local site investigator/radiology\n* Submit an archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated for PD-L1 status determination prior to randomization\n* Has adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known central nervous system (ie, brain and/or spinal cord) metastases and/or carcinomatous meningitis. Participants with treated brain metastases may participate only if they satisfy all of the following: a) Have no evidence of new or enlarging brain metastases confirmed by post-treatment repeat brain imaging performed at least 4 weeks after pretreatment brain imaging, and b) Are neurologically stable without the need for steroids for at least 14 days before first dose of trial treatment as per local site assessment\n* Has severe hypersensitivity to study intervention and/or any of its excipients\n* Has an active autoimmune disease that has required systemic treatment in past 2 years\n* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease\n* Has an active infection requiring systemic therapy\n* Has a known history of human immunodeficiency virus (HIV) infection and/or Hepatitis B infection or known active Hepatitis C infection\n* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study\n* Has symptomatic ascites or pleural effusion. A participant who is clinically stable after treatment for these conditions is eligible\n* Before the first dose of study intervention: a) Has received prior systemic cytotoxic chemotherapy for metastatic NSCLC b) Has received antineoplastic biological therapy for metastatic NSCLC c) Has had major surgery (<3 weeks prior to first dose) d) Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor\n* Received radiation therapy to the lung that is >30 Gray within 6 months of the first dose of study intervention\n* Is expected to require any other form of antineoplastic therapy while on study\n* For participants with nonsquamous histology: Is unable to interrupt aspirin or other Non-steroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g/day, for a 5-day period\n* For participants with nonsquamous histology: Is unable or unwilling to take folic acid or vitamin B12 supplementation\n* Has received prior radiotherapy within 2 weeks of start of study intervention or have had a history of radiation pneumonitis. Participants must have recovered from all radiation-related toxicities and not require corticosteroids. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease\n* Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention\n* Has had an allogenic tissue/solid organ transplant",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Has an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0 or 1",
                    "criterion": "ECOG performance score",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has pathologically (histologically or cytologically) confirmed diagnosis of squamous or nonsquamous non-small cell lung cancer (NSCLC)",
            "criterions": [
                {
                    "exact_snippets": "pathologically (histologically or cytologically) confirmed diagnosis",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnosis of squamous or nonsquamous non-small cell lung cancer (NSCLC)",
                    "criterion": "lung cancer type",
                    "requirements": [
                        {
                            "requirement_type": "cancer type",
                            "expected_value": "non-small cell lung cancer (NSCLC)"
                        },
                        {
                            "requirement_type": "histology subtype",
                            "expected_value": [
                                "squamous",
                                "nonsquamous"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by the local site investigator/radiology",
            "criterions": [
                {
                    "exact_snippets": "Has measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment standard",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male participants are eligible to participate if they agree to use contraception as per protocol unless confirmed to be azoospermic",
            "criterions": [
                {
                    "exact_snippets": "Male participants",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "agree to use contraception as per protocol",
                    "criterion": "contraception use agreement",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless confirmed to be azoospermic",
                    "criterion": "azoospermia",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has not received prior systemic treatment for their metastatic NSCLC. Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease",
            "criterions": [
                {
                    "exact_snippets": "Has not received prior systemic treatment for their metastatic NSCLC",
                    "criterion": "prior systemic treatment for metastatic NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease",
                    "criterion": "adjuvant or neoadjuvant therapy completion time before metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "completion time before metastatic disease",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has confirmation that epidermal growth factor receptor (EGFR), Anaplastic lymphoma kinase (ALK), or ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS1)-directed therapy is not indicated in nonsquamous NSCLC as well as mixed nonsquamous/squamous NSCLC. Participants with purely squamous NSCLC do not require testing",
            "criterions": [
                {
                    "exact_snippets": "confirmation that epidermal growth factor receptor (EGFR)...directed therapy is not indicated in nonsquamous NSCLC as well as mixed nonsquamous/squamous NSCLC",
                    "criterion": "EGFR-directed therapy indication",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmation that...Anaplastic lymphoma kinase (ALK)...directed therapy is not indicated in nonsquamous NSCLC as well as mixed nonsquamous/squamous NSCLC",
                    "criterion": "ALK-directed therapy indication",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmation that...ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS1)-directed therapy is not indicated in nonsquamous NSCLC as well as mixed nonsquamous/squamous NSCLC",
                    "criterion": "ROS1-directed therapy indication",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with purely squamous NSCLC do not require testing",
                    "criterion": "histology (purely squamous NSCLC)",
                    "requirements": [
                        {
                            "requirement_type": "testing requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Submit an archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated for PD-L1 status determination prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Submit an archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated",
                    "criterion": "tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": [
                                "archival",
                                "newly obtained core biopsy",
                                "newly obtained incisional biopsy"
                            ]
                        },
                        {
                            "requirement_type": "irradiation status",
                            "expected_value": "not previously irradiated"
                        }
                    ]
                },
                {
                    "exact_snippets": "for PD-L1 status determination prior to randomization",
                    "criterion": "PD-L1 status determination",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to randomization"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of childbearing potential (WOCBP) or is a WOCBP who agrees of using a contraceptive method per protocol",
            "criterions": [
                {
                    "exact_snippets": "female participant",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "not pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not ... breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not a woman of childbearing potential (WOCBP)",
                    "criterion": "woman of childbearing potential status",
                    "requirements": [
                        {
                            "requirement_type": "WOCBP",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "WOCBP who agrees of using a contraceptive method per protocol",
                    "criterion": "contraceptive use agreement (for WOCBP)",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive use agreement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has Stage IV (T any, N any, M1a, M1b, or M1c - American Joint Committee on Cancer 8th Edition) squamous or nonsquamous NSCLC",
            "criterions": [
                {
                    "exact_snippets": "Stage IV (T any, N any, M1a, M1b, or M1c - American Joint Committee on Cancer 8th Edition)",
                    "criterion": "cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "IV"
                        },
                        {
                            "requirement_type": "T category",
                            "expected_value": "any"
                        },
                        {
                            "requirement_type": "N category",
                            "expected_value": "any"
                        },
                        {
                            "requirement_type": "M category",
                            "expected_value": [
                                "M1a",
                                "M1b",
                                "M1c"
                            ]
                        },
                        {
                            "requirement_type": "staging system",
                            "expected_value": "American Joint Committee on Cancer 8th Edition"
                        }
                    ]
                },
                {
                    "exact_snippets": "squamous or nonsquamous NSCLC",
                    "criterion": "NSCLC histology",
                    "requirements": [
                        {
                            "requirement_type": "histological type",
                            "expected_value": [
                                "squamous",
                                "nonsquamous"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has adequate organ function",
            "criterions": [
                {
                    "exact_snippets": "Has adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Has severe hypersensitivity to study intervention and/or any of its excipients",
            "criterions": [
                {
                    "exact_snippets": "Has severe hypersensitivity to study intervention",
                    "criterion": "hypersensitivity to study intervention",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "Has severe hypersensitivity to ... any of its excipients",
                    "criterion": "hypersensitivity to excipients of study intervention",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease",
            "criterions": [
                {
                    "exact_snippets": "history of (noninfectious) pneumonitis/interstitial lung disease that required steroids",
                    "criterion": "(noninfectious) pneumonitis/interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "required steroids"
                        }
                    ]
                },
                {
                    "exact_snippets": "current pneumonitis/interstitial lung disease",
                    "criterion": "pneumonitis/interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "current presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years",
            "criterions": [
                {
                    "exact_snippets": "Has a known additional malignancy",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is progressing",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "progression status",
                            "expected_value": "progressing"
                        }
                    ]
                },
                {
                    "exact_snippets": "has required active treatment within the past 3 years",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "active treatment requirement",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years ago"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention",
            "criterions": [
                {
                    "exact_snippets": "Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention",
                    "criterion": "live or live attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has had an allogenic tissue/solid organ transplant",
            "criterions": [
                {
                    "exact_snippets": "Has had an allogenic tissue/solid organ transplant",
                    "criterion": "allogenic tissue/solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known central nervous system (ie, brain and/or spinal cord) metastases and/or carcinomatous meningitis. Participants with treated brain metastases may participate only if they satisfy all of the following: a) Have no evidence of new or enlarging brain metastases confirmed by post-treatment repeat brain imaging performed at least 4 weeks after pretreatment brain imaging, and b) Are neurologically stable without the need for steroids for at least 14 days before first dose of trial treatment as per local site assessment",
            "criterions": [
                {
                    "exact_snippets": "Has known central nervous system (ie, brain and/or spinal cord) metastases and/or carcinomatous meningitis",
                    "criterion": "central nervous system metastases or carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with treated brain metastases may participate only if they satisfy all of the following: a) Have no evidence of new or enlarging brain metastases confirmed by post-treatment repeat brain imaging performed at least 4 weeks after pretreatment brain imaging",
                    "criterion": "brain metastases (treated)",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": "no evidence of new or enlarging brain metastases"
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "post-treatment repeat brain imaging performed at least 4 weeks after pretreatment brain imaging"
                        }
                    ]
                },
                {
                    "exact_snippets": "Are neurologically stable without the need for steroids for at least 14 days before first dose of trial treatment as per local site assessment",
                    "criterion": "neurological stability",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "steroid use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention",
            "criterions": [
                {
                    "exact_snippets": "Is currently participating in ... a study of an investigational agent",
                    "criterion": "participation in a study of an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has participated in a study of an investigational agent ... within 4 weeks prior to the first dose of study intervention",
                    "criterion": "prior participation in a study of an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has used an investigational device within 4 weeks prior to the first dose of study intervention",
                    "criterion": "use of an investigational device",
                    "requirements": [
                        {
                            "requirement_type": "time since use",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an active autoimmune disease that has required systemic treatment in past 2 years",
            "criterions": [
                {
                    "exact_snippets": "Has an active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has required systemic treatment in past 2 years",
                    "criterion": "systemic treatment for autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention",
            "criterions": [
                {
                    "exact_snippets": "Has a diagnosis of immunodeficiency",
                    "criterion": "immunodeficiency diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is receiving chronic systemic steroid therapy ... within 7 days prior the first dose of study intervention",
                    "criterion": "chronic systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "receiving_within_days_prior_to_first_dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "is receiving ... any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention",
                    "criterion": "immunosuppressive therapy (other than steroids)",
                    "requirements": [
                        {
                            "requirement_type": "receiving_within_days_prior_to_first_dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Before the first dose of study intervention: a) Has received prior systemic cytotoxic chemotherapy for metastatic NSCLC b) Has received antineoplastic biological therapy for metastatic NSCLC c) Has had major surgery (<3 weeks prior to first dose) d) Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor",
            "criterions": [
                {
                    "exact_snippets": "Has received prior systemic cytotoxic chemotherapy for metastatic NSCLC",
                    "criterion": "prior systemic cytotoxic chemotherapy for metastatic NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has received antineoplastic biological therapy for metastatic NSCLC",
                    "criterion": "prior antineoplastic biological therapy for metastatic NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has had major surgery (<3 weeks prior to first dose)",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "history of major surgery",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor",
                    "criterion": "prior therapy with immune checkpoint inhibitors or agents directed to T-cell receptors",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agent types",
                            "expected_value": [
                                "anti-PD-1",
                                "anti-PD-L1",
                                "anti-PD-L2",
                                "agent directed to another stimulatory or coinhibitory T-cell receptor"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an active infection requiring systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Has an active infection requiring systemic therapy",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is expected to require any other form of antineoplastic therapy while on study",
            "criterions": [
                {
                    "exact_snippets": "Is expected to require any other form of antineoplastic therapy while on study",
                    "criterion": "requirement for other antineoplastic therapy",
                    "requirements": [
                        {
                            "requirement_type": "expectation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known history of human immunodeficiency virus (HIV) infection and/or Hepatitis B infection or known active Hepatitis C infection",
            "criterions": [
                {
                    "exact_snippets": "known history of human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatitis B infection",
                    "criterion": "Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known active Hepatitis C infection",
                    "criterion": "Hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For participants with nonsquamous histology: Is unable to interrupt aspirin or other Non-steroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g/day, for a 5-day period",
            "criterions": [
                {
                    "exact_snippets": "nonsquamous histology",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "nonsquamous"
                        }
                    ]
                },
                {
                    "exact_snippets": "unable to interrupt aspirin or other Non-steroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g/day, for a 5-day period",
                    "criterion": "aspirin or NSAID use",
                    "requirements": [
                        {
                            "requirement_type": "interruptibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interruption_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "aspirin dose exception",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.3,
                                "unit": "g/day"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For participants with nonsquamous histology: Is unable or unwilling to take folic acid or vitamin B12 supplementation",
            "criterions": [
                {
                    "exact_snippets": "participants with nonsquamous histology",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "histology type",
                            "expected_value": "nonsquamous"
                        }
                    ]
                },
                {
                    "exact_snippets": "unable or unwilling to take folic acid or vitamin B12 supplementation",
                    "criterion": "folic acid or vitamin B12 supplementation",
                    "requirements": [
                        {
                            "requirement_type": "ability to take supplementation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "willingness to take supplementation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received radiation therapy to the lung that is >30 Gray within 6 months of the first dose of study intervention",
            "criterions": [
                {
                    "exact_snippets": "Received radiation therapy to the lung",
                    "criterion": "radiation therapy to the lung",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": ">30 Gray within 6 months of the first dose of study intervention",
                    "criterion": "radiation therapy to the lung",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "Gray"
                            }
                        },
                        {
                            "requirement_type": "time since therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has symptomatic ascites or pleural effusion. A participant who is clinically stable after treatment for these conditions is eligible",
            "criterions": [
                {
                    "exact_snippets": "Has symptomatic ascites",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has ... pleural effusion",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "A participant who is clinically stable after treatment for these conditions is eligible",
                    "criterion": "clinical stability after treatment for ascites or pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "clinical stability after treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study",
            "criterions": [
                {
                    "exact_snippets": "Has a known psychiatric or substance abuse disorder",
                    "criterion": "psychiatric disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a known psychiatric or substance abuse disorder",
                    "criterion": "substance abuse disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "would interfere with the participant's ability to cooperate with the requirements of the study",
                    "criterion": "ability to cooperate with study requirements",
                    "requirements": [
                        {
                            "requirement_type": "interference by disorder",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received prior radiotherapy within 2 weeks of start of study intervention or have had a history of radiation pneumonitis. Participants must have recovered from all radiation-related toxicities and not require corticosteroids. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease",
            "criterions": [
                {
                    "exact_snippets": "Has received prior radiotherapy within 2 weeks of start of study intervention",
                    "criterion": "prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last radiotherapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "have had a history of radiation pneumonitis",
                    "criterion": "history of radiation pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants must have recovered from all radiation-related toxicities",
                    "criterion": "recovery from radiation-related toxicities",
                    "requirements": [
                        {
                            "requirement_type": "recovery",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not require corticosteroids",
                    "criterion": "requirement for corticosteroids",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease",
                    "criterion": "palliative radiation to non-CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "duration of radiotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}